Quest for the right Drug
גלוקוז % 5 לעירוי לתוך הוריד BP GLUCOSE 5 % INTRAVENOUS INFUSION BP (GLUCOSE MONOHYDRATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תמיסה לאינפוזיה : SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8. Undesirable effects Undesirable effects which occurred in patients treated with Glucose 5% from the post-marketing experience are tabulated below. The adverse drug reactions listed in this section are given following the recommended frequency convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); and not known (cannot be estimated from the available data). Tabulated list of adverse reactions System Organ Class Adverse reaction (MedDRA term) Frequency Anaphylactic reaction* Immune system disorders Not known Hypersensitivity* Electrolyte imbalance Hypokalaemia Hypomagnesaemia Metabolism and nutrition Hypophosphatemia Not known disorders Hyperglycaemia Dehydration Hypervolaemia Hospital acquired hyponatraemia** Nervous system disorders Hyponatraemic encephalopathy** Not known Skin and subcutaneous Rash Not known tissue disorders Venous thrombosis Vascular disorders Not known Phlebitis Renal and urinary disorders Polyuria Not known Chills* Pyrexia* Infusion site infection General disorders and Infusion site irritation for example Not known administration site erythema conditions Extravasation Local reaction Pain localised *Potential manifestation in patients with allergy to corn, see section 4.4 ** Hospital acquired hyponatraemia may cause irreversible brain injury and death due to development of acute hyponatraemic encephalopathy (see section 4.4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום
מידע נוסף